Clinical trial recruitment continues to be a critical barrier to progress in translational medicine, with recent estimates suggesting that up to 86% of trials experience delays due to enrollment challenges. This results in significant financial losses for sponsors, estimated at over $600,000 per day, while patients face extended waiting times for access to potentially life-saving therapies.
Trially®, a U.S.-based company developing AI-driven recruitment solutions, today announced a $4.7 million funding round and the launch of Margo, an agentic AI designed to streamline the conversion of eligible patient matches into trial participants.
Trially’s platform integrates three key functions:
- Trially Match: Applies HIPAA-compliant large language model agents to parse and analyze unstructured electronic health record data, identifying patients who meet trial eligibility criteria.
- Trially Connect: Uses conversational AI for direct engagement with patients, performing pre-screening and facilitating enrollment.
- Trially Intelligence: Provides trial feasibility analytics, alerting sites and sponsors to opportunities that align with existing patient populations.
Trially’s proprietary AI has improved our ability to pre-screen candidates, reducing the time and resources typically spent on manual EHR chart reviews while improving the diversity and quality of our patient pools.
Sam Searcy, Chief Commercial Officer, ClinTrial Research
Reported Performance Metrics
- Preliminary performance data released by Trially indicate:
- A 2–6-fold increase in monthly enrollment for complex trials
- Approximately 95% accuracy in screening against eligibility criteria
- 73% reduction in screen failures through improved matching
- 91% reduction in billable staff time for chart review
- Tenfold increase in trial candidate identification rates
- A $4 million revenue increase at one research site network within three months
Recruitment has always been the bottleneck in clinical research. With Margo, we’re not just matching patients, we’re engaging and enrolling them. That’s what sets Trially apart: we can identify patients with ~95% screening accuracy and then agentic AI can engage them at the exact moment it matters most.
Kyle McAllister, Co-founder and CEO of Trially
From the investment perspective, Thad Langford, Founding Partner at Flyover Capital (which led the funding round alongside Alpaca, Atria, Blu Ventures, Looking Glass Capital, Redbud, The Council, and Gaingels), noted that recruitment has been a long-standing bottleneck in clinical research, with Trially offering one of the first end-to-end automated solutions.
With the new funding, Trially plans to expand adoption across clinical research sites, pharmaceutical sponsors, CROs, and physician networks. The company highlights regulatory compliance (HIPAA, SOC 2, FDA CFR 21 Part 11, ISO 27001) as a core component of its infrastructure.